Silence Therapeutics to Present at the 2021 SVB Leerink Global Healthcare Conference
Silence Therapeutics, AIM: SLN and Nasdaq: SLN, will present at the 2021 SVB Leerink Global Healthcare Conference on February 26th at 9:20 a.m. EST. CEO Mark Rothera will provide a company update, focusing on their innovative siRNA therapeutics aimed at significant unmet medical needs. A live webcast will be available on Silence's website, with a replay following the event. The company's proprietary platform is pivotal for developing medicines targeting disease-associated genes, including product candidates SLN360 and SLN124.
- None.
- None.
Silence Therapeutics to Present at the 2021 SVB Leerink Global Healthcare Conference
18 February 2021
LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that its President and Chief Executive Officer, Mark Rothera, will present a company update at the virtual 2021 SVB Leerink Global Healthcare Conference on Friday, February 26th at 9:20 a.m. EST / 14:20 GMT.
A live webcast of the presentation can be accessed via the Investors section of the Company's website at www.silence-therapeucs.com. An archived replay of the webcast will be available on the Company's website following the conference.
Enquiries:
| Silence Therapeutics plc Gem Hopkins, Head of IR and Corporate Communications ir@silence-therapeutics.com | Tel: +1 (646) 637-3208 |
| Investec Bank plc (Nominated Adviser and Broker) Daniel Adams/Gary Clarence | Tel: +44 (0) 20 7597 5970 |
| European IR Consilium Strategic Communications Mary-Jane Elliott/ Angela Gray / Chris Welsh silencetherapeutics@consilium-comms.com | Tel: +44 (0) 20 3709 5700 |
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary messenger RNAi GOLD™ (GalNAc Oligonucleotide Discovery) Platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.
FAQ
When is Silence Therapeutics presenting at the 2021 SVB Leerink Global Healthcare Conference?
Who is the CEO of Silence Therapeutics?
What is the focus of Silence Therapeutics' presentation at the conference?
Where can I watch the Silence Therapeutics presentation?
What are the main product candidates of Silence Therapeutics?
What technology does Silence Therapeutics use for drug development?
